Related Experiment Video

Updated: May 12, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

16.8K

Direct medical costs of polyarthritis in a pediatric hospital in Mexico

María F Carrillo-Vega1, Juan M Mireles-Dorantes2, Samara Mendienta-Zerón3

  • 1Dirección de Investigación, Instituto Nacional de Geriatría, Mexico City.

Boletin Medico Del Hospital Infantil De Mexico
|November 22, 2024
PubMed

Insights

The direct medical costs for polyarticular juvenile idiopathic arthritis (JIA) in Mexico are substantial, driven primarily by expensive biologic disease-modifying drugs (bDMARDs). Cost-saving strategies, such as including generic bDMARDs, are recommended.

Area of Science:

  • Pediatric Rheumatology
  • Health Economics
  • Pharmacoeconomics

Background:

  • Juvenile idiopathic arthritis (JIA) is the most prevalent rheumatic disease in children.
  • The polyarticular course of JIA affects a majority of pediatric patients.
  • Understanding the economic burden of JIA is crucial for healthcare resource allocation.

Purpose of the Study:

  • To determine the direct medical costs (DMC) associated with polyarticular JIA in pediatric patients.
  • To analyze cost components and identify major drivers of expenditure.
  • To provide economic data from a tertiary hospital in Mexico.

Main Methods:

  • Retrospective cost analysis from the perspective of a Mexican tertiary hospital (HMI).
  • Inclusion of pediatric patients with polyarticular JIA treated between January and September 2022.
  • Cost components included consultations, medications, hospitalization, and laboratory studies over a 12-year horizon.

Main Results:

  • The mean 10-year direct medical cost for polyarticular JIA was approximately $4,555.2 USD.
  • Medications constituted the largest cost component at 82.7%, largely due to biologic disease-modifying drugs (bDMARDs) at 95.3% of drug costs.
  • Office/laboratory studies (8.4%), hospitalization (8.0%), and consultations (1.8%) comprised the remaining costs.

Conclusions:

  • Biologic disease-modifying drugs (bDMARDs) represent the most significant cost driver for polyarticular JIA, particularly by the second year of treatment.
  • Reviewing institutional purchasing prices for medications is essential.
  • Incorporating generic bDMARDs into treatment protocols could reduce overall healthcare expenditure.
Abstract

Keywords:
Artritis idiopática juvenilCostos médicos directosDirect medical costsJuvenile idiopathic arthritisMexicoMéxicoPoliartritisPolyarthritis

More Related Videos

Knee Arthrocentesis in Adults04:41

Knee Arthrocentesis in Adults

Published on: February 25, 2022

7.3K
Maintenance of a Lateral Fluid Percussion Injury Device05:16

Maintenance of a Lateral Fluid Percussion Injury Device

Published on: April 21, 2023

849

Related Concept Videos

Secondary Healthcare System01:11

Secondary Healthcare System

Secondary healthcare is offered by a specialist, generally in hospitals or clinics for patients referred by primary healthcare providers. It occurs when a person has an illness or injury that requires specific medical care. Secondary care is often referred to as acute care. Secondary care can range from uncomplicated care to repair a minor laceration or treat a strep throat infection to more complicated emergent care, such as treating a head injury sustained in an automobile accident. Whatever...
Fractures: Bone Repair01:27

Fractures: Bone Repair

Treatment for a fracture is based on the type of break, the bone affected, and the patient's age.
Minor fractures with no bone displacement are treated by immobilizing the fractured bone using a cast or splint. However, in the case of fractures with displaced bones, the broken bones are repositioned before immobilization to ensure successful healing without deformation and loss of function. The realignment of fractured bone ends is performed through a process called reduction. If the procedure...
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...